APO Research
Talk to an analyst

APO RESEARCH · REPORT

Parkinson's Disease Treatments

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Parkinson's Disease Treatments Market Analysis and Forecast 2026-2032

22 December 2025193 pages

Choose your research edition.

Industry ResearchParkinson's Disease Treatments Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Parkinson's Disease Treatments Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Parkinson's Disease Treatments Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Parkinson's Disease Treatments Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Parkinson's Disease Treatments Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Parkinson's Disease Treatments market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Parkinson's Disease Treatments is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Parkinson's Disease Treatments is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Parkinson's Disease Treatments is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Parkinson's Disease Treatments is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Parkinson's Disease Treatments include GSK, Teva, Sun Pharma, Novartis, Merck, Abbvie, Wockhardt, UCB and Lundbeck, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Parkinson's Disease Treatments, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Parkinson's Disease Treatments, also provides the revenue of main regions and countries. Of the upcoming market potential for Parkinson's Disease Treatments, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Parkinson's Disease Treatments revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Parkinson's Disease Treatments market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Parkinson's Disease Treatments revenue, projected growth trends, production technology, application and end-user industry.

Parkinson's Disease Treatments Segment by Company

GSK

Teva

Sun Pharma

Novartis

Merck

Abbvie

Wockhardt

UCB

Lundbeck

Impax

Boehringer Ingelheim

Bausch Health

Acadia

Parkinson's Disease Treatments Segment by Type

COMT Inhibitors Anticholinergics

MAO-B Inhibitors

Apomorphine

Dopamine Agonists

Glutamate Antagonist

Levodopa

Other Drugs

Parkinson's Disease Treatments Segment by Application

Hospitals

Healthcare Institutes

Others

Parkinson's Disease Treatments Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Parkinson's Disease Treatments market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Parkinson's Disease Treatments and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Parkinson's Disease Treatments.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Parkinson's Disease Treatments in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Parkinson's Disease Treatments company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Parkinson's Disease Treatments revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Parkinson's Disease Treatments Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. COMT Inhibitors Anticholinergics Major Player Table 3. MAO-B Inhibitors Major Player Table 4. Apomorphine Major Player Table 5. Dopamine Agonists Major Player Table 6. Glutamate Antagonist Major Player Table 7. Levodopa Major Player Table 8. Other Drugs Major Player Table 9. Global Parkinson's Disease Treatments Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 10. Hospitals Major Player Table 11. Healthcare Institutes Major Player Table 12. Others Major Player Table 13. Parkinson's Disease Treatments Industry Trends Table 14. Parkinson's Disease Treatments Industry Drivers Table 15. Parkinson's Disease Treatments Industry Opportunities and Challenges Table 16. Parkinson's Disease Treatments Industry Restraints Table 17. Global Parkinson's Disease Treatments Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 18. Global Parkinson's Disease Treatments Market Size by Region (2021-2026) & (US$ Million) Table 19. Global Parkinson's Disease Treatments Market Share by Region (2021-2026) Table 20. Global Parkinson's Disease Treatments Market Size by Region (2027-2032) & (US$ Million) Table 21. Global Parkinson's Disease Treatments Market Share by Region (2027-2032) Table 22. Global Parkinson's Disease Treatments Revenue by Players (US$ Million) & (2021-2026) Table 23. Global Parkinson's Disease Treatments Revenue Market Share by Players (2021-2026) Table 24. Global Parkinson's Disease Treatments Key Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Parkinson's Disease Treatments Key Players Headquarters & Area Served Table 26. Global Parkinson's Disease Treatments Players, Product Type & Application Table 27. Global Parkinson's Disease Treatments Players Establishment Date Table 28. Global Players Market Concentration Ratio (CR5 and HHI) Table 29. Global Parkinson's Disease Treatments by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 30. Global Parkinson's Disease Treatments Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Parkinson's Disease Treatments Revenue by Type (2021-2026) & (US$ Million) Table 32. Global Parkinson's Disease Treatments Revenue by Type (2027-2032) & (US$ Million) Table 33. Global Parkinson's Disease Treatments Revenue Market Share by Type (2021-2026) Table 34. Global Parkinson's Disease Treatments Revenue Market Share by Type (2027-2032) Table 35. Global Parkinson's Disease Treatments Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Parkinson's Disease Treatments Revenue by Application (2021-2026) & (US$ Million) Table 37. Global Parkinson's Disease Treatments Revenue by Application (2027-2032) & (US$ Million) Table 38. Global Parkinson's Disease Treatments Revenue Market Share by Application (2021-2026) Table 39. Global Parkinson's Disease Treatments Revenue Market Share by Application (2027-2032) Table 40. GSK Company Information Table 41. GSK Business Overview Table 42. GSK Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. GSK Parkinson's Disease Treatments Product Portfolio Table 44. GSK Recent Development Table 45. Teva Company Information Table 46. Teva Business Overview Table 47. Teva Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Teva Parkinson's Disease Treatments Product Portfolio Table 49. Teva Recent Development Table 50. Sun Pharma Company Information Table 51. Sun Pharma Business Overview Table 52. Sun Pharma Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Sun Pharma Parkinson's Disease Treatments Product Portfolio Table 54. Sun Pharma Recent Development Table 55. Novartis Company Information Table 56. Novartis Business Overview Table 57. Novartis Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Novartis Parkinson's Disease Treatments Product Portfolio Table 59. Novartis Recent Development Table 60. Merck Company Information Table 61. Merck Business Overview Table 62. Merck Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Merck Parkinson's Disease Treatments Product Portfolio Table 64. Merck Recent Development Table 65. Abbvie Company Information Table 66. Abbvie Business Overview Table 67. Abbvie Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Abbvie Parkinson's Disease Treatments Product Portfolio Table 69. Abbvie Recent Development Table 70. Wockhardt Company Information Table 71. Wockhardt Business Overview Table 72. Wockhardt Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Wockhardt Parkinson's Disease Treatments Product Portfolio Table 74. Wockhardt Recent Development Table 75. UCB Company Information Table 76. UCB Business Overview Table 77. UCB Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. UCB Parkinson's Disease Treatments Product Portfolio Table 79. UCB Recent Development Table 80. Lundbeck Company Information Table 81. Lundbeck Business Overview Table 82. Lundbeck Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Lundbeck Parkinson's Disease Treatments Product Portfolio Table 84. Lundbeck Recent Development Table 85. Impax Company Information Table 86. Impax Business Overview Table 87. Impax Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. Impax Parkinson's Disease Treatments Product Portfolio Table 89. Impax Recent Development Table 90. Boehringer Ingelheim Company Information Table 91. Boehringer Ingelheim Business Overview Table 92. Boehringer Ingelheim Parkinson's Disease Treatments Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Boehringer Ingelheim Parkinson's Disease Treatments Product Portfolio Table 94. Boehringer Ingelheim Recent Development Table 95. Bausch Health Company Information Table 96. Bausch Health Business Overview Table 97. Bausch Health Parkinson's Disease Treatments Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Bausch Health Parkinson's Disease Treatments Product Portfolio Table 99. Bausch Health Recent Development Table 100. Acadia Company Information Table 101. Acadia Business Overview Table 102. Acadia Parkinson's Disease Treatments Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Acadia Parkinson's Disease Treatments Product Portfolio Table 104. Acadia Recent Development Table 105. North America Parkinson's Disease Treatments Revenue by Type (2021-2026) & (US$ Million) Table 106. North America Parkinson's Disease Treatments Revenue by Type (2027-2032) & (US$ Million) Table 107. North America Parkinson's Disease Treatments Revenue by Application (2021-2026) & (US$ Million) Table 108. North America Parkinson's Disease Treatments Revenue by Application (2027-2032) & (US$ Million) Table 109. North America Parkinson's Disease Treatments Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. North America Parkinson's Disease Treatments Revenue by Country (2021-2026) & (US$ Million) Table 111. North America Parkinson's Disease Treatments Revenue by Country (US$ Million) & (2027-2032) Table 112. Europe Parkinson's Disease Treatments Revenue by Type (2021-2026) & (US$ Million) Table 113. Europe Parkinson's Disease Treatments Revenue by Type (2027-2032) & (US$ Million) Table 114. Europe Parkinson's Disease Treatments Revenue by Application (2021-2026) & (US$ Million) Table 115. Europe Parkinson's Disease Treatments Revenue by Application (2027-2032) & (US$ Million) Table 116. Europe Parkinson's Disease Treatments Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. Europe Parkinson's Disease Treatments Revenue by Country (2021-2026) & (US$ Million) Table 118. Europe Parkinson's Disease Treatments Revenue by Country (US$ Million) & (2027-2032) Table 119. China Parkinson's Disease Treatments Revenue by Type (2021-2026) & (US$ Million) Table 120. China Parkinson's Disease Treatments Revenue by Type (2027-2032) & (US$ Million) Table 121. China Parkinson's Disease Treatments Revenue by Application (2021-2026) & (US$ Million) Table 122. China Parkinson's Disease Treatments Revenue by Application (2027-2032) & (US$ Million) Table 123. Asia Parkinson's Disease Treatments Revenue by Type (2021-2026) & (US$ Million) Table 124. Asia Parkinson's Disease Treatments Revenue by Type (2027-2032) & (US$ Million) Table 125. Asia Parkinson's Disease Treatments Revenue by Application (2021-2026) & (US$ Million) Table 126. Asia Parkinson's Disease Treatments Revenue by Application (2027-2032) & (US$ Million) Table 127. Asia Parkinson's Disease Treatments Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 128. Asia Parkinson's Disease Treatments Revenue by Region (US$ Million) & (2021-2026) Table 129. Asia Parkinson's Disease Treatments Revenue by Region (US$ Million) & (2027-2032) Table 130. SAMEA Parkinson's Disease Treatments Revenue by Type (2021-2026) & (US$ Million) Table 131. SAMEA Parkinson's Disease Treatments Revenue by Type (2027-2032) & (US$ Million) Table 132. SAMEA Parkinson's Disease Treatments Revenue by Application (2021-2026) & (US$ Million) Table 133. SAMEA Parkinson's Disease Treatments Revenue by Application (2027-2032) & (US$ Million) Table 134. SAMEA Parkinson's Disease Treatments Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 135. SAMEA Parkinson's Disease Treatments Revenue by Country (2021-2026) & (US$ Million) Table 136. SAMEA Parkinson's Disease Treatments Revenue by Country (US$ Million) & (2027-2032) Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Parkinson's Disease Treatments Image Figure 2. Global Parkinson's Disease Treatments Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Parkinson's Disease Treatments Market Size Share 2021 VS 2025 VS 2032 Figure 4. COMT Inhibitors Anticholinergics Image Figure 5. MAO-B Inhibitors Image Figure 6. Apomorphine Image Figure 7. Dopamine Agonists Image Figure 8. Glutamate Antagonist Image Figure 9. Levodopa Image Figure 10. Other Drugs Image Figure 11. Global Parkinson's Disease Treatments Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Parkinson's Disease Treatments Market Size Share 2021 VS 2025 VS 2032 Figure 13. Hospitals Image Figure 14. Healthcare Institutes Image Figure 15. Others Image Figure 16. Global Parkinson's Disease Treatments Market Size (US$ Million) & (2021-2032) Figure 17. Global Parkinson's Disease Treatments Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Parkinson's Disease Treatments Market Share by Region: 2021 VS 2025 VS 2032 Figure 19. Global Parkinson's Disease Treatments Players Revenue Share Top 10 and Top 5 in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Parkinson's Disease Treatments Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Parkinson's Disease Treatments Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Parkinson's Disease Treatments Revenue Market Share by Type (2021-2032) Figure 24. Global Parkinson's Disease Treatments Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Parkinson's Disease Treatments Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 26. Global Parkinson's Disease Treatments Revenue Market Share by Application (2021-2032) Figure 27. North America Parkinson's Disease Treatments Revenue YoY Growth (2021-2032) & (US$ Million) Figure 28. North America Parkinson's Disease Treatments Revenue Share by Type (2021-2032) Figure 29. North America Parkinson's Disease Treatments Revenue Share by Application (2021-2032) Figure 30. North America Parkinson's Disease Treatments Revenue Share by Country (2021-2032) Figure 31. United States Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Canada Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Mexico Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Europe Parkinson's Disease Treatments Revenue YoY Growth (2021-2032) & (US$ Million) Figure 35. Europe Parkinson's Disease Treatments Revenue Share by Type (2021-2032) Figure 36. Europe Parkinson's Disease Treatments Revenue Share by Application (2021-2032) Figure 37. Europe Parkinson's Disease Treatments Revenue Share by Country (2021-2032) Figure 38. Germany Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. France Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. U.K. Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Italy Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Spain Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Russia Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Netherlands Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Nordic Countries Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. China Parkinson's Disease Treatments Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. China Parkinson's Disease Treatments Revenue Share by Type (2021-2032) Figure 48. China Parkinson's Disease Treatments Revenue Share by Application (2021-2032) Figure 49. Asia Parkinson's Disease Treatments Revenue YoY Growth (2021-2032) & (US$ Million) Figure 50. Asia Parkinson's Disease Treatments Revenue Share by Type (2021-2032) Figure 51. Asia Parkinson's Disease Treatments Revenue Share by Application (2021-2032) Figure 52. Asia Parkinson's Disease Treatments Revenue Share by Region (2021-2032) Figure 53. Japan Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. South Korea Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. India Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Australia Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Taiwan Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Southeast Asia Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. SAMEA Parkinson's Disease Treatments Revenue YoY Growth (2021-2032) & (US$ Million) Figure 60. SAMEA Parkinson's Disease Treatments Revenue Share by Type (2021-2032) Figure 61. SAMEA Parkinson's Disease Treatments Revenue Share by Application (2021-2032) Figure 62. SAMEA Parkinson's Disease Treatments Revenue Share by Country (2021-2032) Figure 63. Brazil Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Argentina Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Chile Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Colombia Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Peru Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Saudi Arabia Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Israel Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. UAE Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Turkey Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Iran Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Egypt Parkinson's Disease Treatments Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • COMT Inhibitors Anticholinergics
  • MAO-B Inhibitors
  • Apomorphine
  • Dopamine Agonists
  • Glutamate Antagonist
  • Levodopa
  • Other Drugs
Applications
  • Hospitals
  • Healthcare Institutes
  • Others
Companies covered
  • GSK
  • Teva
  • Sun Pharma
  • Novartis
  • Merck
  • Abbvie
  • Wockhardt
  • UCB
  • Lundbeck
  • Impax
  • Boehringer Ingelheim
  • Bausch Health
  • Acadia

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Parkinson's Disease Treatments Market by Type
  3. 1.2.1 Global Parkinson's Disease Treatments Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 COMT Inhibitors Anticholinergics
  5. 1.2.3 MAO-B Inhibitors
  6. 1.2.4 Apomorphine
  7. 1.2.5 Dopamine Agonists
  8. 1.2.6 Glutamate Antagonist
  9. 1.2.7 Levodopa
  10. 1.2.8 Other Drugs
  11. 1.3 Parkinson's Disease Treatments Market by Application
  12. 1.3.1 Global Parkinson's Disease Treatments Market Size by Application, 2021 VS 2025 VS 2032
  13. 1.3.2 Hospitals
  14. 1.3.3 Healthcare Institutes
  15. 1.3.4 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Parkinson's Disease Treatments Market Dynamics
  1. 2.1 Parkinson's Disease Treatments Industry Trends
  2. 2.2 Parkinson's Disease Treatments Industry Drivers
  3. 2.3 Parkinson's Disease Treatments Industry Opportunities and Challenges
  4. 2.4 Parkinson's Disease Treatments Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Parkinson's Disease Treatments Market Perspective (2021-2032)
  2. 3.2 Global Parkinson's Disease Treatments Growth Trends by Region
  3. 3.2.1 Global Parkinson's Disease Treatments Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Parkinson's Disease Treatments Market Size by Region (2021-2026)
  5. 3.2.3 Global Parkinson's Disease Treatments Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Parkinson's Disease Treatments Revenue by Players
  2. 4.1.1 Global Parkinson's Disease Treatments Revenue by Players (2021-2026)
  3. 4.1.2 Global Parkinson's Disease Treatments Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Parkinson's Disease Treatments Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Parkinson's Disease Treatments Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Parkinson's Disease Treatments Key Players Headquarters & Area Served
  7. 4.4 Global Parkinson's Disease Treatments Players, Product Type & Application
  8. 4.5 Global Parkinson's Disease Treatments Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Parkinson's Disease Treatments Market CR5 and HHI
  11. 4.6.3 2025 Parkinson's Disease Treatments Tier 1, Tier 2, and Tier 3
5 Parkinson's Disease Treatments Market Size by Type
  1. 5.1 Global Parkinson's Disease Treatments Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Parkinson's Disease Treatments Revenue by Type (2021-2032)
  3. 5.3 Global Parkinson's Disease Treatments Revenue Market Share by Type (2021-2032)
6 Parkinson's Disease Treatments Market Size by Application
  1. 6.1 Global Parkinson's Disease Treatments Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Parkinson's Disease Treatments Revenue by Application (2021-2032)
  3. 6.3 Global Parkinson's Disease Treatments Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 GSK
  2. 7.1.1 GSK Company Information
  3. 7.1.2 GSK Business Overview
  4. 7.1.3 GSK Parkinson's Disease Treatments Revenue and Gross Margin (2021-2026)
  5. 7.1.4 GSK Parkinson's Disease Treatments Product Portfolio
  6. 7.1.5 GSK Recent Developments
  7. 7.2 Teva
  8. 7.2.1 Teva Company Information
  9. 7.2.2 Teva Business Overview
  10. 7.2.3 Teva Parkinson's Disease Treatments Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Teva Parkinson's Disease Treatments Product Portfolio
  12. 7.2.5 Teva Recent Developments
  13. 7.3 Sun Pharma
  14. 7.3.1 Sun Pharma Company Information
  15. 7.3.2 Sun Pharma Business Overview
  16. 7.3.3 Sun Pharma Parkinson's Disease Treatments Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sun Pharma Parkinson's Disease Treatments Product Portfolio
  18. 7.3.5 Sun Pharma Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis Parkinson's Disease Treatments Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novartis Parkinson's Disease Treatments Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 Merck
  26. 7.5.1 Merck Company Information
  27. 7.5.2 Merck Business Overview
  28. 7.5.3 Merck Parkinson's Disease Treatments Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Merck Parkinson's Disease Treatments Product Portfolio
  30. 7.5.5 Merck Recent Developments
  31. 7.6 Abbvie
  32. 7.6.1 Abbvie Company Information
  33. 7.6.2 Abbvie Business Overview
  34. 7.6.3 Abbvie Parkinson's Disease Treatments Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Abbvie Parkinson's Disease Treatments Product Portfolio
  36. 7.6.5 Abbvie Recent Developments
  37. 7.7 Wockhardt
  38. 7.7.1 Wockhardt Company Information
  39. 7.7.2 Wockhardt Business Overview
  40. 7.7.3 Wockhardt Parkinson's Disease Treatments Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Wockhardt Parkinson's Disease Treatments Product Portfolio
  42. 7.7.5 Wockhardt Recent Developments
  43. 7.8 UCB
  44. 7.8.1 UCB Company Information
  45. 7.8.2 UCB Business Overview
  46. 7.8.3 UCB Parkinson's Disease Treatments Revenue and Gross Margin (2021-2026)
  47. 7.8.4 UCB Parkinson's Disease Treatments Product Portfolio
  48. 7.8.5 UCB Recent Developments
  49. 7.9 Lundbeck
  50. 7.9.1 Lundbeck Company Information
  51. 7.9.2 Lundbeck Business Overview
  52. 7.9.3 Lundbeck Parkinson's Disease Treatments Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Lundbeck Parkinson's Disease Treatments Product Portfolio
  54. 7.9.5 Lundbeck Recent Developments
  55. 7.10 Impax
  56. 7.10.1 Impax Company Information
  57. 7.10.2 Impax Business Overview
  58. 7.10.3 Impax Parkinson's Disease Treatments Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Impax Parkinson's Disease Treatments Product Portfolio
  60. 7.10.5 Impax Recent Developments
  61. 7.11 Boehringer Ingelheim
  62. 7.11.1 Boehringer Ingelheim Company Information
  63. 7.11.2 Boehringer Ingelheim Business Overview
  64. 7.11.3 Boehringer Ingelheim Parkinson's Disease Treatments Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Boehringer Ingelheim Parkinson's Disease Treatments Product Portfolio
  66. 7.11.5 Boehringer Ingelheim Recent Developments
  67. 7.12 Bausch Health
  68. 7.12.1 Bausch Health Company Information
  69. 7.12.2 Bausch Health Business Overview
  70. 7.12.3 Bausch Health Parkinson's Disease Treatments Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Bausch Health Parkinson's Disease Treatments Product Portfolio
  72. 7.12.5 Bausch Health Recent Developments
  73. 7.13 Acadia
  74. 7.13.1 Acadia Company Information
  75. 7.13.2 Acadia Business Overview
  76. 7.13.3 Acadia Parkinson's Disease Treatments Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Acadia Parkinson's Disease Treatments Product Portfolio
  78. 7.13.5 Acadia Recent Developments
8 North America
  1. 8.1 North America Parkinson's Disease Treatments Revenue (2021-2032)
  2. 8.2 North America Parkinson's Disease Treatments Revenue by Type (2021-2032)
  3. 8.2.1 North America Parkinson's Disease Treatments Revenue by Type (2021-2026)
  4. 8.2.2 North America Parkinson's Disease Treatments Revenue by Type (2027-2032)
  5. 8.3 North America Parkinson's Disease Treatments Revenue Share by Type (2021-2032)
  6. 8.4 North America Parkinson's Disease Treatments Revenue by Application (2021-2032)
  7. 8.4.1 North America Parkinson's Disease Treatments Revenue by Application (2021-2026)
  8. 8.4.2 North America Parkinson's Disease Treatments Revenue by Application (2027-2032)
  9. 8.5 North America Parkinson's Disease Treatments Revenue Share by Application (2021-2032)
  10. 8.6 North America Parkinson's Disease Treatments Revenue by Country
  11. 8.6.1 North America Parkinson's Disease Treatments Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Parkinson's Disease Treatments Revenue by Country (2021-2026)
  13. 8.6.3 North America Parkinson's Disease Treatments Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Parkinson's Disease Treatments Revenue (2021-2032)
  2. 9.2 Europe Parkinson's Disease Treatments Revenue by Type (2021-2032)
  3. 9.2.1 Europe Parkinson's Disease Treatments Revenue by Type (2021-2026)
  4. 9.2.2 Europe Parkinson's Disease Treatments Revenue by Type (2027-2032)
  5. 9.3 Europe Parkinson's Disease Treatments Revenue Share by Type (2021-2032)
  6. 9.4 Europe Parkinson's Disease Treatments Revenue by Application (2021-2032)
  7. 9.4.1 Europe Parkinson's Disease Treatments Revenue by Application (2021-2026)
  8. 9.4.2 Europe Parkinson's Disease Treatments Revenue by Application (2027-2032)
  9. 9.5 Europe Parkinson's Disease Treatments Revenue Share by Application (2021-2032)
  10. 9.6 Europe Parkinson's Disease Treatments Revenue by Country
  11. 9.6.1 Europe Parkinson's Disease Treatments Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Parkinson's Disease Treatments Revenue by Country (2021-2026)
  13. 9.6.3 Europe Parkinson's Disease Treatments Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Parkinson's Disease Treatments Revenue (2021-2032)
  2. 10.2 China Parkinson's Disease Treatments Revenue by Type (2021-2032)
  3. 10.2.1 China Parkinson's Disease Treatments Revenue by Type (2021-2026)
  4. 10.2.2 China Parkinson's Disease Treatments Revenue by Type (2027-2032)
  5. 10.3 China Parkinson's Disease Treatments Revenue Share by Type (2021-2032)
  6. 10.4 China Parkinson's Disease Treatments Revenue by Application (2021-2032)
  7. 10.4.1 China Parkinson's Disease Treatments Revenue by Application (2021-2026)
  8. 10.4.2 China Parkinson's Disease Treatments Revenue by Application (2027-2032)
  9. 10.5 China Parkinson's Disease Treatments Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Parkinson's Disease Treatments Revenue (2021-2032)
  2. 11.2 Asia Parkinson's Disease Treatments Revenue by Type (2021-2032)
  3. 11.2.1 Asia Parkinson's Disease Treatments Revenue by Type (2021-2026)
  4. 11.2.2 Asia Parkinson's Disease Treatments Revenue by Type (2027-2032)
  5. 11.3 Asia Parkinson's Disease Treatments Revenue Share by Type (2021-2032)
  6. 11.4 Asia Parkinson's Disease Treatments Revenue by Application (2021-2032)
  7. 11.4.1 Asia Parkinson's Disease Treatments Revenue by Application (2021-2026)
  8. 11.4.2 Asia Parkinson's Disease Treatments Revenue by Application (2027-2032)
  9. 11.5 Asia Parkinson's Disease Treatments Revenue Share by Application (2021-2032)
  10. 11.6 Asia Parkinson's Disease Treatments Revenue by Country
  11. 11.6.1 Asia Parkinson's Disease Treatments Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Parkinson's Disease Treatments Revenue by Country (2021-2026)
  13. 11.6.3 Asia Parkinson's Disease Treatments Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Parkinson's Disease Treatments Revenue (2021-2032)
  2. 12.2 SAMEA Parkinson's Disease Treatments Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Parkinson's Disease Treatments Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Parkinson's Disease Treatments Revenue by Type (2027-2032)
  5. 12.3 SAMEA Parkinson's Disease Treatments Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Parkinson's Disease Treatments Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Parkinson's Disease Treatments Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Parkinson's Disease Treatments Revenue by Application (2027-2032)
  9. 12.5 SAMEA Parkinson's Disease Treatments Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Parkinson's Disease Treatments Revenue by Country
  11. 12.6.1 SAMEA Parkinson's Disease Treatments Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Parkinson's Disease Treatments Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Parkinson's Disease Treatments Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst